Zoledronic acid
Zoledronic acid is a pharmaceutical drug with 244 clinical trials. Currently 12 active trials ongoing. Historical success rate of 85.1%.
Success Metrics
Based on 165 completed trials
Phase Distribution
Phase Distribution
23
Early Stage
55
Mid Stage
141
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
81.7%
165 of 202 finished
18.3%
37 ended early
12
trials recruiting
244
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
Clinical Trials (244)
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Romosozumab Use to Build Skeletal Integrity
FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA
Muscle Impact of Treating Osteoporosis
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
CHronic Nonbacterial Osteomyelitis International Registry
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 244